AIM: A retrospective evaluation of the results of treatment of myopic choroidal neovascularization (mCNV) with intravitreal injections of ranibizumab in a pro re nata (PRN) regimen in three groups of patients distributed according to axial length. METHODS: The paper presents a retrospective multicenter study carried out with the cooperation of several Departments of Ophthalmology in the Czech Republic. The study included 60 eyes of 60 patients suffering from mCNV, divided according to axial length into three groups. The first group consisted of 20 patients with an axial length of the eyes shorter than 28 mm (Group 1), the second group included 27 patients with axial lengths ranging from 28 mm to 29.81 mm (Group 2), and 13 patients had axial lengths longer than 30 mm (Group 3). All patients were first administered 3 initial intravitreal ranibizumab injections at monthly intervals (loading phase), and other injections were administered according to a PRN treatment regimen. Patients were evaluated before treatment and then at intervals of 3, 6, 9, and 12 months. The effect of ranibizumab treatment on the functional and morphological parameters of the affected eye was evaluated. RESULTS: The average baseline BCVA ± SD in Group 1 was 52.6 ± 12.5 letters of ETDRS optotypes, and at the end of the one-year follow-up, it was 63.3 ± 11.8 letters. The average baseline of CRT ± SD in this group was 377.4 ± 80.0 μm, and in the 12th month, it was 311.1 ± 63.7 μm. The average baseline BCVA ± SD in Group 2 was 50.2 ± 9.0 ETDRS letters, and at the end of the follow-up, it was 60 ± 12.4 letters. The average baseline of CRT ± SD in Group 2 was 391.2 ± 85.2 μm, and in the 12th month, it was 323.9 ± 91.2 μm. In Group 3, the average baseline of BCVA was 48.5 ± 14.5 ETDRS letters, and at the end of the one-year follow-up, it was 55.7 ± 16.1 letters. The average baseline CRT ± SD for Group 3 was 342.1 ± 94.9 μm, and after 12 months, it was 287.8 ± 88.4 μm. An improvement of BCVA by ≥15 letters of ETDRS optotypes was achieved by 3 patients of 20 (15%) in Group 1, by 5 patients of 27 (18.5%) in Group 2, and by 3 patients of 13 (23.1%) in Group 3. All these changes were statistically significant in comparison with the input values (p < 0.05). CONCLUSION: Ranibizumab treatment in patients with mCNV in our study resulted in statistically significant improvement in BCVA and a decrease in CRT in all groups of patients. Our results from a routine clinical practice correspond with the results of large clinical studies; we confirm a particularly good effect of treatment in patients with axial lengths of the eye smaller than 28 mm.

Department of Ophthalmology 3rd Faculty of Medicine Charles University Prague and University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Ophthalmology Faculty of Medicine in Hradec Kralove Charles University Prague and University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Ophthalmology Faculty of Medicine Masaryk University Hospital Brno Czech Republic

Department of Ophthalmology Faculty of Medicine University of Ostrava and University Hospital Ostrava Ostrava Czech Republic

Zobrazit více v PubMed

Wong T. Y., Foster P. J., Hee J., et al. Prevalence and risk factors for refractive errors in adult Chinese in Singapore. Investigative Ophthalmology & Visual Science. 2000;41(41):2486–2494. PubMed

Fredrick D. R. Myopia. BMJ. 2002;324(7347):1195–1199. PubMed PMC

Miller D. G., Singerman L. J. Natural history of choroidal neovascularization in high myopia. Current Opinion in Ophthalmology. 2001;12(3):222–224. doi: 10.1097/00055735-200106000-00014. PubMed DOI

Neelam K., Cheung C. M. G., Ohno-Matsui K., Lai T. Y. Y., Wong T. Y. Choroidal neovascularization in pathological myopia. Progress in Retinal and Eye Research. 2012;31(5):495–525. doi: 10.1016/j.preteyeres.2012.04.001. PubMed DOI

Curtin B. J. The Myopias: Basic Science and Clinical Management. Philadelphia, PA, USA: Harper & Row; 1985. The prevalence of myopia.

Grossniklaus H. E., Green W. R. Pathologic findings in pathologic myopia. Retina. 1992;12(2):127–133. doi: 10.1097/00006982-199212020-00009. PubMed DOI

Vongphanit J., Mitchell P., Wang J. J. Prevalence and progression of myopic retinopathy in an older population. Ophthalmology. 2002;109(4):704–711. doi: 10.1016/s0161-6420(01)01024-7. PubMed DOI

Liu H. H., Xu L., Wang Y. X., Wang S., You Q. S., Jonas J. B. Prevalence and progression of myopic retinopathy in Chinese adults: the Beijing Eye Study. Ophthalmology. 2010;117(9):1763–1768. doi: 10.1016/j.ophtha.2010.01.020. PubMed DOI

Curtin B. J., Karlin D. B. Axial length measurements and fundus changes of the myopic eye. I. The posterior fundus. Transactions of the American Ophthalmological Society. 1970;68(68):312–334. PubMed PMC

Hayashi K., Ohno-Matsui K., Shimada N., et al. Long-term pattern of progression of myopic maculopathy. Ophthalmology. 2010;117(8):1595–1611. doi: 10.1016/j.ophtha.2009.11.003. PubMed DOI

Wong T. Y., Ferreira A., Hughes R., Carter G., Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. American Journal of Ophthalmology. 2014;157(1):9–25. doi: 10.1016/j.ajo.2013.08.010. PubMed DOI

Narayanan R., Kuppermann B. D., Jones C., Kirkpatrick P. Ranibizumab. Nature Reviews Drug Discovery. 2006;5(10):815–816. doi: 10.1038/nrd2157. PubMed DOI

Lai T. Y. Y., Chan W.-M., Liu D. T. L., Lam D. S. C. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina. 2009;29(6):750–756. doi: 10.1097/iae.0b013e31819ed6bd. PubMed DOI

Monés J. M., Amselem L., Serrano A., Garcia M., Hijano M. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye. 2009;23(6):1275–1281. doi: 10.1038/eye.2009.88. PubMed DOI

Lalloum F., Souied E. H., Bastuji-Garin S., et al. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina. 2010;30(3):399–406. doi: 10.1097/iae.0b013e3181bcef24. PubMed DOI

Calvo-Gonzalez C., Reche-Frutos J., Donate J., Fernandez-Perez C., Garcia-Feijoo J. Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment. American Journal of Ophthalmology. 2011;151(3):529–534. doi: 10.1016/j.ajo.2010.09.021. PubMed DOI

Lorenzo D., Arias L., Alcubierre R., et al. Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month follow-up. Ophthalmologica. 2011;226(3):103–109. doi: 10.1159/000328980. PubMed DOI

Wu T.-T., Kung Y.-H. The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization. Journal of Ocular Pharmacology and Therapeutics. 2012;28(2):129–133. doi: 10.1089/jop.2011.0106. PubMed DOI PMC

Wolf S., Balciuniene V. J., Laganovska G., et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121(3):682–692. doi: 10.1016/j.ophtha.2013.10.023. PubMed DOI

Wong T. Y., Ohno-Matsui K., Leveziel N., et al. Myopic choroidal neovascularisation: current concepts and update on clinical management. British Journal of Ophthalmology. 2015;99(3):289–296. doi: 10.1136/bjophthalmol-2014-305131. PubMed DOI PMC

Cohen S. Y. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina. 2009;29(8):1062–1066. doi: 10.1097/iae.0b013e3181b1bb1a. PubMed DOI

Yoon J. U., Byun Y. J., Koh H. J. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina. 2010;30(3):418–424. doi: 10.1097/iae.0b013e3181bd2fe4. PubMed DOI

Holz F. G., Tufail A., Leveziel N., et al. Ranibizumab in myopic choroidal neovascularization: a subgroup Analysis by ethnicity, age, and ocular characteristics in radiance. Ophthalmologica. 2016;236(1):19–28. doi: 10.1159/000446027. PubMed DOI

Seasonal Variations in Ocular Axial Length Increase among Children in the Czech Republic